LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS

Pai Life Sciences, Inc., Seattle WA

Investigators

Abstract

The proprietary combination adjuvants AS01 and AS04 are used in approved vaccines (Shingrix and Cervarix, respectively). Another successful adjuvant, GLA-SE, is currently in late-stage clinical trials. To make these classes of adjuvants available to vaccine developers, the contractor is developing functional mimics for low-cost and effective vaccines against emerging diseases and to address major health gaps worldwide.